Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer's Disease
PITTSBURGH, July 16 /PRNewswire/ -- Cognition Therapeutics Inc., a Pittsburgh-based drug discovery company developing small molecule disease-modifying treatments for Alzheimer's, has closed on a $1.21M Series A financing. The round was led by Ogden CAP, LLC of New York City and inc...
Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases
TAMPA, Fla., May 5 /PRNewswire-USNewswire/ -- The Tampa Lions Eye Institute for Transplant and Research, Inc. (LEITR) today announced plans to open a new 12,000-square-foot facility in Tampa, Florida. This state-of-the-art facility will offer high-volume, high-quality human ocular tissue for resea...
Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study
- 12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea -
NAPA, Calif., May 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that targ...
Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc.
today announced it has raised $50 million in a private equity financing.
This capital will be utilized to support the ongoing Phase 3 development
program evaluating linaclotide for the treatment of irritable bowel
NJ-Based Surgeon Helps Pioneer Dramatic Advance in Treating Damaged Discs
Total Disc Replacement implant represents newest alternative surgical treatment
Dr. Carl Giordano - based in Morristown - among first surgeons selected to provide operation
Dramatic reduction in post-surgery pain and stiffness; quicker ...
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire/ -- Portola
Pharmaceuticals, Inc., a privately-held biotechnology company focused on
the discovery and development of novel therapeutics for cardiovascular and
inflammatory diseases, announced today that is has raised $60 million in a
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems
Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies into Clinical Trials in Ovarian Cancer
PHILADELPHIA, TOKYO and WOBURN, Mass, J...
Continued Funding to Help Advance 'Exciting Moment' in Diabetes Research
American Diabetes Association and Richard and Susan Smith Family
Foundation Announce Renewed Commitment to Diabetes Gene Study
ALEXANDRIA, Va., April 30 /PRNewswire-USNewswire/ -- The American
Diabetes Association (ADA) has announced research projects to study newly
discovered human type 2...
Women Invited to Join New Health Registry to Advance Research
CHICAGO, March 13 /PRNewswire-USNewswire/ -- Women throughout the state
are invited to help advance
research in women's health by joining the new
Illinois Women's Health Registry. The registry, created by the Institute
for Women's Health Research at Northwestern University's Feinberg School of...
Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
Harris Expands Enterprise Intelligence Systems to Healthcare Market
ORLANDO, Fla., Feb. 25 /PRNewswire-FirstCall/ -- HIMSS, Booth #1841 --
Harris Corporation (NYSE: HRS ), an international communications and
information technology company, has joined forces with Cancer Treatment
American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
Research presented this week at American Society for Reproductive Medicine meeting could significantly improve ability to identify embryos that present high risk of birth defects or miscarriage for IVF patients
AFA supports efforts to bring advanced screening technology to patients as
BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
BRISBANE, Calif., Sept. 25 /PRNewswire/ -- BiPar Sciences, Inc., a
privately held biopharmaceutical company developing novel cancer therapies,
today announced that it has hired industry veterans Eric D. Malek as vice
president of corporate development and Deborah A. Thomas as vice president
NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
SOPHIA ANTIPOLIS, France, Sept. 11 /PRNewswire/ -- NicOx S.A.
(Eurolist: COX) today reported that TOPIGEN Pharmaceuticals Inc. has
disclosed promising top-line results from its first phase 2 clinical study
for TPI-1020, a new chemical entity licensed from NicOx which is a novel
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Multi-Center International Study to Determine the Efficacy of LBH589 in Patients with Relapsed or Refractory Multiple Myeloma
NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma
Research Consortium (MMRC) today announced its participation in a Phase II
study to dete...
Next Safety, Inc.'s Innovative Drug Delivery System Will Replace
Cigarettes and Significantly Advance Pulmonary Medication Delivery
WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,
Inc. has identified basic scientific mechanisms that promise to
revolutionize pulmonary drug delivery. This proprietary technology
uses a stream of purified air to deliver medications deep into the
pulmonary system. It is considered...
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
... the future.
"The implantation of this kind of device on any organ and the ability to deliver medication to the affected organ, could be a huge advance
in how we currently treat cancer," Dr. Murphree said. This work is done in conjunction with Ricardo Carvalho, M.D., Ph.D. and the company 3T Ophthalmi...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
... first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC).
"We believe that these data document an important advance
for patients with metastatic colorectal cancer," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen....
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...m financial benefits that enable us to continue to advance
the technology and fill the pipeline with more exc...rugs that Isis' satellite companies are developing advance
in clinical development.
Isis benefits from its partners as they advance
RNA-based technologies and develop drugs that inco...
Cancer Centers of North Carolina Offers HDR Brachytherapy for Treatment of Cancerous Tumors
...nts through the addition of High Dose Rate (HDR) brachytherapy. This latest advance
in brachytherapy allows physicians to deliver precise radiation treatment t...y, as well as best-in-class clinical and operational processes that help to advance
the quality, safety and cost effectiveness of cancer care. For more informa...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
... durations of treatment and a more rapid reduction in fracture risk in the severe osteoporotic postmenopausal population, which would be a significant advance
in the treatment of this debilitating disease."
About the Phase 2 Clinical Trial
The Phase 2 randomized, placebo- and comparator-controlled...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
...ne. Nektar's technology has been shown to increase oral bioavailability and inhibit penetration across the blood-brain barrier, an important potential advance
for small molecule therapies. The product is being developed to treat opioid-induced constipation (OIC).
NKTR-102, PEGylated irinotecan, is cu...
DNA Helps Reunite Children With Their Families
...iving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance
personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technolo...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
...ty database. Two ovarian cancer patients have been enrolled in the study to date, and it is anticipated 6 to 12 patients will be enrolled this year in advance
of enrolling patients in trial evaluating ProLindac in combination with other chemotherapies. Access recently announced data from a recurrent ovarian ...
Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
...it is completely disposable, eliminating the
very costly sterilization process commonly associated with endoscopic
"We are proud to advance
our visualization capabilities with Tower, the
leading specialty semiconductor manufacturer and foremost CMOS image sensor
provider," said Dr. Elazar ...
VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
...nt from the spleen to inflammatory sites, including myocardial infarction. The findings are expected to open up new areas of research and potentially advance
therapeutic approaches to key disease areas including inflammation and myocardial injury.
In the SCIENCE report, entitled " Identification of...
New Powder Speeds Healing of Difficult Foot Wounds
...A) 97th Annual Scientific Meeting in Toronto, July 30 - August 2, 2009, and will highlight the powder's unique ability to rapidly heal foot wounds and advance
the treatment patients currently receive.
(Logo: http://www.newscom.com/cgi-bin/prnh/20090730/DC54472LOGO )
This wound powder is especially...
Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty-Plus Year Historic Relationship
...in areas such as heart disease, cancer, pediatrics, transplant, and neurosciences; to create a model teaching environment for the 21st century; and to advance
the health of the communities we serve."
The new long-term agreement demonstrates a renewed level of commitment that will align key strategic d...
Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced
...esident R&D, Danone Research. "We hope the two young investigators will advance
our knowledge in the growing field of probiotics and provide insight to bet...DANONE and Yakult Honsha Co., Ltd. The role of the GPC is to promote and/or advance
probiotics in the world, through means such as:
Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
...'s ability to successfully conduct clinical development of LX1032 and preclinical and clinical development of its other potential drug candidates, advance
additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain pat...
Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
...concept study in HCV-infected patients, we plan to advance
IDX184 into a 14-day dose-ranging study in combina...ibavirin, to determine the optimal IDX184 doses to advance
into broader clinical trials."
In the 75.... There can be no guarantees that the company will advance
any clinical product candidate or other component ...
Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results
...n the lives of the 1.5 million Americans, and millions more worldwide, who suffer from this devastating autoimmune illness."
"This is a major advance
for patients, families, and physicians--the entire lupus community!" said Richard Furie, MD, chief of the division of rheumatology and allergy-clinica...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
...evelopment with positive results. We look forward to completing the pivotal studies, with the hope of bringing this potentially important therapeutic advance
to patients suffering from SLE."
Key Findings from BLISS-52
"The BLISS-52 results support and extend the findings that emerged in ...
AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
...s to maximize the potential of this platform through a mixture of in-house and partnered programs. The AlphaVax technology is currently being used to advance
vaccines for cytomegalovirus, herpes simplex virus, respiratory syncytial virus, a range of cancers, influenza, HIV and a number of biodefense targets...
University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test
...st that a type-specific, quantitative PCR-MS based test may be an important advance
in the early detection of cervical cancer."
...ion that a type specific quantitative PCR-MS based test may be an important advance
in the early detection of cervical cancer, the future prospects and potenti...
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
...an in early 2000 (nearly 400 patients), a panel of experts strongly endorses moving forward to complete the final phase of clinical trials (MARVEL) to advance
muscle stem cell (myoblast) therapy for treating heart failure to mainstream use with FDA approval and CMS reimbursement. The MARVEL II program aims ...
MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
...tting During First Year of Life; Reinforcing Commitment to Pediatric Research
GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune continues to advance
its commitment to pediatric research with today's announcement of the first observational prospective study designed to assess the burden of respirato...
Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
...istant depression and approved by a multi-disciplinary team." Ongoing advances in DBS technologies represent an important new field that could greatly advance
the understanding of psychiatric neurobiology, according to the review.
A peer-review journal, Mayo Clinic Proceedings publishes original article...
AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
...r, anesthesiologist Dr. Neil Singla, CEO of Lotus Clinical Research Inc., Pasadena, CA, stated, "The ARX-01 product has the potential to offer a major advance
in the management of inpatient acute pain, liberating patients from the IV connection to a PCA pump, while still providing effective pain control appr...
Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
...es of VA106483. The trial involved 27 elderly men aged 65 years or
more with a history of nocturia.
Based on these results, Vantia now plans to advance
VA106483 into a
larger Phase IIb clinical efficacy study in the second half of 2009.
Dr Jim Phillips, CEO of Vantia Therapeutics, said 'VA10648...
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
...rd-looking statements include dependence on King's ability to conduct its presentations as planned; dependence on the Company's ability to continue to advance
the development of its pipeline products as planned; dependence on the high cost and uncertainty of research, clinical trials, and other development a...